The Products Pipeline
Our Lead Compound GF-1002
A 120-minute infusion of AAV vectors facilitates a secure, temporary expression of additional copies of a centenarian variant of the SIRT6 gene. This method ensures that the gene does not integrate into the host DNA and poses no risk of self-replication. Also, it avoids the transfer of bacterial genetic material and mitigates concerns related to immune reactions or mutagenesis.
Pre Clinical Stage GF-1002
GF-1002 is a suspension of an AAV vector-based gene therapy for intravenous infusion and intends to improve DNA maintenance by delivering extra copies of the CentenarianVariant. The AAV gene therapy works by modifying (or ‘recombining’) a natural AAV to produce a safe and efficient vector to deliver a transgene into cells. The transgene is the ’gene of interest’ (“GOI”) to be provided to the cells. In the case of GF-1002, the GOI is the coding sequence of the Centenarian Variant.
Pre Clinical Stage GF-4001
GF-4001 is a non-Human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs).
Pre Clinical Stage GF-3001
GF-3001 ﾠis an formulation of an adeno-associated viral vector-based gene therapy. It is a recombinant AAV with fibroblast tropism containing a transgene encoding the cDNA portion of a variant of the human SIRT6 gene found in centenarians for delivery to the dermal fibroblast
Clinical Programs
First in human proof-of-concept phase I/II trial in Werner Syndrome
Genflow Biosciences is rapidly emerging as a leading biotechnology company in the field of longevity. With an aggressive clinical development plan in progress, our team of life science leaders and researchers are driving our mission forward determined to achieve short-term milestones.
Our Partners
Innovation requires collaboration with other leading organisations in longevity and gene delivery
